Zymergen

Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zymergen Inc. (NASDAQ: ZY) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Zymergen's April 2021 initial public offering (the “IPO” or “Offering”). A class action lawsuit has already been filed. If you wish to serve as lea

ZY INVESTOR ALERT: Rosen Law Firm Encourages Zymergen Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – ZY

Investors need to pay close attention to Zymergen (ZY) stock based on the movements in the options market lately.

Implied Volatility Surging for Zymergen (ZY) Stock Options

SAN FRANCISCO, Aug. 6, 2021 /PRNewswire/ -- Hagens Berman urges Zymergen Inc. (NASDAQ: ZY) investors with significant losses to submit your losses now.     Class Period: Apr. 20, 2021 – Aug. 4, 2021 Lead Plaintiff Deadline: Oct. 4, 2021 Visit: www.hbsslaw.com/investor-fraud/ZY Contact An Attorney Now: ZY@hbsslaw.com                                               844-916-0895 Zymergen Inc. (ZY) Securities Class Action: The case arises from Zymergen's misrepresentations in its Registration Statement for its Apr. 23, 2021 IPO concerning Hyaline, the Company's primary product that remains in the customer qualification stage.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Zymergen (ZY) Investors to Contact Firm's Attorneys Now, Securities Class Action Filed

SAN DIEGO, Aug. 6, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Zymergen class action lawsuit charges Zymergen Inc. (NASDAQ: ZY), certain of its officers and directors, and the underwriters of Zymergen's April 2021 initial public offering ("IPO") with violations of the Securities Act of 1933 and seeks to represent purchasers of Zymergen common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Zymergen's IPO.  The Zymergen class action lawsuit was filed in the Northern District of California on August 4, 2021 and captioned Shankar v.

ZY NOTICE: Investors with Substantial Losses Have Opportunity to Lead the Zymergen Inc. Class Action Lawsuit

New Orleans, Louisiana--(Newsfile Corp. - August 5, 2021) -  Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have until October 4, 2021 to file lead plaintiff applications in a securities class action lawsuit against Zymergen Inc. (NASDAQ: ZY), if they purchased the Company's shares issued in connection with its April 2021 initial public stock offering...

Zymergen Investor Notice by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors of Lead Plaintiff Deadline in Class Action Lawsuits Against Zymergen Inc. - ZY

The stock price of Zymergen Inc (NASDAQ: ZY) increased by 75.15%. This is why it happened.

ZY Stock Price Increased 75.15%: Why It Happened

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased or otherwise acquired Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY) securities pursuant and/or traceable to the offering documents issued in connection with Zymergen's April 2021 initial public offering (the

ZYMERGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Zymergen Inc. and Encourages Investors to Contact the Firm

EMERYVILLE, Calif., Aug. 5, 2021 /PRNewswire/ -- Zymergen Inc. (Nasdaq: ZY) today announced the appointments of Lincoln Germain as Chief Commercial Officer and Subodh Deshmukh as Chief Development Officer.

Zymergen Announces Executive Appointments, Strengthening Leadership Team in Key Areas

Zymergen Inc (NASDAQ: ZY) shares are trading higher, rebounding after the stock fell sharply on Wednesday. The stock dipped in the prior session after the company said it 'no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.

What In The World Is Going On With Zymergen's Stock Today?

SAN DIEGO--(BUSINESS WIRE)-- #ZYstock--The suit alleges defendants issued false statements concerning Zymergen business and prospects, resulting in its stock trading at inflated prices.

ZY ALERT: Investors with Substantial Losses Have Opportunity to Lead the Zymergen Inc. Class Action Lawsuit

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company's April 2021 initial public offering (“IPO” or the “Offering”). Zymergen investors have until October 4, 2021 to file a le

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Zymergen Inc. Investors

It has been a crazy week for this synthetic-biology upstart -- and the week's not even over yet.

Why Zymergen's Stock Is Skyrocketing Today

The Ark Genomic Revolution ETF bought more than 2.5 million shares of the company on Wednesday, bringing its stake to more than 3.5 million shares.

Zymergen rebounds with a 76% rally after Cathie Wood's Ark Invest tripled its stake in the synthetic biology company

NEW YORK--(BUSINESS WIRE)-- #ZY--INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Zymergen Inc. (ZY) and October 4th Deadline

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Zymergen Inc. (ZY) and October 4th Deadline

Boston, Massachusetts--(Newsfile Corp. - August 5, 2021) -  Block & Leviton is investigating Zymergen, Inc. (NASDAQ: ZY) for potential securities law violations. Investors who have lost money in their Zymergen investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/zymergen.What is this all about?Zymergen went public about four months ago and today admitted that sales of its only product, Hyaline, are struggling, a major target...

ZYMERGEN INVESTIGATION: Block & Leviton Investigates Zymergen For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

SAN FRANCISCO, Aug. 5, 2021 /PRNewswire/ -- Hagens Berman urges Zymergen Inc. (NASDAQ: ZY) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Zymergen (ZY) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

Los Angeles, California--(Newsfile Corp. - August 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zymergen Inc. ("Zymergen" or "the Company") (NASDAQ: ZY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Zymergen disclosed in a business update released on August 3, 2021, that...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zymergen Inc. and Encourages Investors with Losses to Contact the Firm

Shares in Biofacturing company Zymergen (ZY) collapsed in epic fashion after a catastrophic setback in its commercialization plans.

Zymergen: How To Buy A Disaster

A bullish Ark Invest on Wednesday more than doubled its stake in Zymergen Inc (NASDAQ: ZY) after it plummeted due to the company's “immaterial” revenue warning. The Cathie Wood-led New York-based investment management firm snapped up 2.46 million shares, estimated to be worth about $20.4 million, in Zymergen on the day shares of the company closed 76.31% lower at $8.25, far below its initial public offering price of $31.

As Zymergen Crashes 76%, Cathie Wood Piles Up $2.5M Worth Of Shares

MILWAUKEE, Aug. 5, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Zymergen (NASDAQ: ZY). The investigation results from inaccurate statements Zymergen may have made regarding its business operations and prospects.

Recover Losses: Ademi LLP Investigates Claims of Securities Fraud against Zymergen, Inc.

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY) on behalf of Zymergen stockholders. Our investigation concerns whether Zymergen has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 3, 2021, after the market closed, Zymergen issued a business u

ZYMERGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Zymergen Inc. on Behalf of Zymergen Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $ZY #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Shankar v. Zymergen Inc., et al., (Case No. 21-cv-06028) on behalf of persons and entities that purchased or otherwise acquired Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Re

ZY CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Lawsuit Against Zymergen Inc. on Behalf of Investors

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Zymergen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 4, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY).If you suffered losses exceeding $50,000 investing in Zymergen stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/ZY.

Zymergen Investor Alert

BERWYN, Pa., Aug. 4, 2021 /PRNewswire/ -- RM LAW, P.C.

RM LAW Announces Investigation of Zymergen Inc.

LOS ANGELES--(BUSINESS WIRE)---- $ZY #ZY--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zymergen Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zymergen Inc. and Encourages Investors with Losses to Contact the Firm

News for Zymergen Stock (ZY)